ClinicalTrials.gg
RecruitingNCT06977269STIM-SMAUpdated Jun 18, 2025

Safety and Tolerability of Low Motoneuron Stimulation Via Transcranial Magnetic Stimulation in Spinal Muscular Atrophy

An interventional study of High-frequency repetitive transcranial magnetic stimulation and lumbar puncture in Spinal Muscular Atrophy (SMA), sponsored by Charitable Foundation Children with Spinal Muscular Atrophy. Recruiting at 1 site in Ukraine. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Charitable Foundation Children with Spinal Muscular Atrophy · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

There is a general physiological rule that any organ or system needs some minimal amount of activity to prevent its atrophy or degeneration. Although the relevance of that rule to exercises in neuromuscular patients and for SMA in particular is not definitely proven, clinical observations seem to support this assumption. Also there are several experimental studies which provide additional support for utility of exercise for SMA.

However, making regular exercises may be very challenging with SMA not only due to physical limitations, but due to psychological either.

While being considered as safe and well tolerated intervention, TMS is able to mimic effects of real physical exercises, at least at the level of low motoneuron, it also provides several advantages. For example, possibility to exercise non-collaborative infants, minimization of psychological motivation impact in adults and/or ability to involve very weak muscle groups.

02

Conditions studied

  • Spinal Muscular Atrophy (SMA)

Keywords

  • spinal muscular atrophy
  • Survival Motor Neuron protein (SMN)
  • Neurofilament (NF)
  • transcranial magnetic stimulation (TMS)
03

In context

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

This study's planned enrollment of 20 is below the median of 29 across 156 interventional studies indexed under Muscular Atrophy, Spinal.

Browse Muscular Atrophy, Spinal studies →

Lead sponsor

Charitable Foundation Children with Spinal Muscular Atrophy is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a diagnosis of 5q-autosomal recessive SMA confirmed by DNA test.
  • .
  • A minimum score of 1 for Entry Item "A" of the Revised Upper Limb Module (RULM) scale for SMA: "Can use hands to hold pencil or pick up a coin/token or drive a powered chair, use phone key pad"

Exclusion criteria

Exclusion Criteria:

  • Subject has severe joint contractures that would affect ability to perform study measures, determined by the study physician.
  • Subject has a deconditioned respiratory system, per the discretion of the physician investigator.
  • Subject has behavioral or cognitive problems that preclude participation in the study, in the opinion of the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    TMS arm

    Stimulation (HF-rTMS) of the primary motor cortex, M1 area of the limbs, at a frequency above 5 Hz and an intensity of 90-100% of the resting motor threshold (RMT), over 10 sessions, up to 2400 stimuli per session.

    Device: High-frequency repetitive transcranial magnetic stimulation · Diagnostic Test: lumbar puncture

Interventions

  • DeviceHigh-frequency repetitive transcranial magnetic stimulation

    High-frequency repetitive transcranial magnetic stimulation targeting the primary motor cortex (M1) of the limbs, delivered at a frequency above 5 Hz and an intensity of 90-100% of the resting motor threshold, across 10 sessions with up to 2400 stimuli per session, is a standard intervention used in various neurological disorders. However, its effects have not been studied in patients with spinal muscular atrophy (SMA).

    Also known as: HF-rTMS

  • Diagnostic testlumbar puncture

    Cerebrospinal fluid sampling to measure SMN protein and neurofilament concentrations before and after the TMS intervention.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Motor Function Measure Scale

    Motor Function Measure (MFM) scale measurement before and after TMS sessions

    Time frame: The first assessment will be conducted before the initial TMS session, and the second will be performed one to two days after the final TMS session.

  2. Change from Baseline of the Revised Upper Limb Module

    Revised Upper Limb Module (RULM) scale measurement before and after TMS sessions

    Time frame: The first assessment will be conducted before the initial TMS session, and the second will be performed one to two days after the final TMS session.

  3. Change from Baseline of the Hammersmith Functional Motor Scale - Expanded

    Hammersmith Functional Motor Scale - Expanded (HFMSE) measurement before and after TMS sessions

    Time frame: The first assessment will be conducted before the initial TMS session, and the second will be performed one to two days after the final TMS session.

  4. Change from Baseline in the 6-Minute Walk Test

    6-Minute Walk Test (6MWT) measurement before and after TMS sessions

    Time frame: The first assessment will be conducted before the initial TMS session, and the second will be performed one to two days after the final TMS session.

07

Study locations

1 of 1 sites recruiting
  • P.V. Voloshyn Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine
    Kharkiv, 61068, Ukraine
    Recruiting
    • Olena Pisotska Medical Director, MD, PhD · Contactinpn@ukr.net · 380577384194
08

References and documents

Individual participant data

Plan to share: Yes — only IPD used in the results publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2025, 7 months after the start.

Of 49 non-industry interventional studies with no phase under Muscular Atrophy, Spinal, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 7 months is below that.

Counting every sponsor, half of 58 studies reached it within 27 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 18, 2025
StartActual
May 19, 2025
Primary completionEst.
Dec 2025
CompletionEst.
Jan 2026
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06977269
Lead sponsor
Charitable Foundation Children with Spinal Muscular Atrophy
Collaborators
P.V. Voloshyn Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine
Responsible party
Sponsor
First posted
May 18, 2025
Start date
May 19, 2025
Primary completion
Dec 2025 (estimated)
Completion
Jan 2026 (estimated)
Last update
Jun 18, 2025

Study contacts

Vitaliy M Matyushenko
Contact
csma.ua@gmail.com
380503640673
Andriy V Shatillo, MD, PhD
Contact
shatil@ukr.net
380978111884
Olena V Pisotska, MD, PhD
principal investigator · P.V. Voloshyn Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine
Andriy V Shatillo, MD, PhD
study chair · P.V. Voloshyn Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion